Cost comparison of efanesoctocog alfa vs conventional factor VIII therapies for major surgeries in patients with severe hemophilia A
Open Access
- 31 March 2026
- journal article
- Published by Elsevier in Blood Vessels, Thrombosis & Hemostasis
- Vol. 3 (3) , 100166
Abstract
No abstract availableKeywords
Funding Information
- Sanofi
This publication has 19 references indexed in Scilit:
- Efanesoctocog Alfa versus Standard and Extended Half-Life Factor VIII Prophylaxis in Adolescent and Adult Patients with Haemophilia A without InhibitorsAdvances in Therapy, 2024
- Perioperative Management of Hemophilia PatientsCurrent Anesthesiology Reports, 2024
- Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia ANew England Journal of Medicine, 2023
- Optimising prophylaxis in haemophilia A: The ups and downs of treatmentBlood Reviews, 2021
- Occurrence rates of haemophilia among males in the United States based on surveillance conducted in specialized haemophilia treatment centresHaemophilia, 2020
- Perioperative haemostasis with full‐length, PEGylated, recombinant factor VIII with extended half‐life (rurioctocog alfa pegol) in patients with haemophilia A: Final results of a multicentre, single‐arm phase III trialHaemophilia, 2019
- First report on the safety and efficacy of an extended half‐life glycoPEGylated recombinant FVIII for major surgery in severe haemophilia AHaemophilia, 2017
- Budget Impact Analysis of Prolonged Half-Life Recombinant FVIII Therapy for Hemophilia in the United StatesValue in Health, 2016
- Musculoskeletal Complications of HemophiliaHSS Journal®: The Musculoskeletal Journal of Hospital for Special Surgery, 2010
- Surgery in Hemophilia. The General View: Patient Selection, Timing, and Preoperative AssessmentSeminars in Hematology, 2006